Screener
Zevra Therapeutics, Inc. ZVRA Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $39.66M+53.3% | $36.22M+77.5% | $34.13M+183% | $26.06M+605% | $25.88M+482% | ||
| $1.53M-87.7% | $1.9M+41.0% | $1.52M+11.3% | $1.24M-46.2% | $12.38M+246% | ||
| $38.14M+182% | $34.32M+80.1% | $32.61M+205% | $24.83M+1,683% | $13.5M+1,441% | ||
| 96.2%+44.0pp | 94.8%+1.4pp | 95.5%+6.9pp | 95.2%+57.6pp | 52.2%+32.5pp | ||
| $4.49M+30.7% | $4.39M+34.8% | $2.62M-68.6% | $3.43M-68.6% | $3.43M-67.4% | ||
| $16.56M-20.3% | $20.78M+6.3% | $20.35M+26.2% | $16.94M+4.5% | $20.78M+64.9% | ||
| $21.05M-13.1% | $25.18M+10.4% | $22.97M-6.1% | $20.37M-25.0% | $24.22M+4.7% | ||
| $16.78M+124% | $52.15M+1,073% | —— | $4.14M+115% | -$71.04M-199% | ||
| 42.3%+317pp | 144%+170pp | —— | 15.9%+755pp | -274.5%+260pp | ||
| $0-100% | $1.71M-13.1% | $1.95M-11.2% | $2.05M-11.3% | $2.01M-4.8% | ||
| -$3.98M-103% | -$7.34M-313% | $3.35M+168% | -$5.12M+13.5% | $147.95M+3,655% | ||
| $12.79M-83.4% | $44.8M+2,437% | $12.67M+162% | -$977K+97.1% | $76.91M+487% | ||
| $4.04M+83.8% | $6.91M+485% | $501K-96.7% | -$433K— | $2.2M+3,041% | ||
| $8.75M-88.3% | $37.89M+1,323% | $12.17M+134% | -$544K+98.4% | $74.71M+475% | ||
| 22.1%-267pp | 104.6%+120pp | 35.6%+332pp | -2.1%+897pp | 288.7%+737pp | ||
| $0.14-88.4% | $0.60+1,100% | $0.19+128% | -$0.01+98.6% | $1.21+352% | ||
| $17.14M+125% | $52.51M+1,514% | $14.98M+209% | $4.54M+118% | -$69.39M-212% | ||
| 43.2%+311pp | 145%+163pp | 43.9%+158pp | 17.4%+713pp | -268.1%+232pp | ||
| $16.78M+124% | $52.15M+1,073% | $14.61M+195% | $4.14M+115% | -$71.04M-199% |
FAQ
- What is Zevra Therapeutics, Inc.'s revenue?
- Zevra Therapeutics, Inc. (ZVRA) generated $136.1M in revenue over the trailing twelve months, up 119.4% year over year.
- Is Zevra Therapeutics, Inc. profitable?
- Zevra Therapeutics, Inc. reported $58.3M in net income over the trailing twelve months, a 42.8% net margin.
- What are Zevra Therapeutics, Inc.'s profit margins?
- Gross margin is 95.5% and operating margin is -103.9%, with a 42.8% net margin.
- What is Zevra Therapeutics, Inc.'s earnings per share?
- Zevra Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $0.92.
- Where does Zevra Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
